Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Trial Profile

A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2019

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CELESTIAL
  • Sponsors Exelixis
  • Most Recent Events

    • 04 Jun 2019 Results of a retrospective analysis assessing association of adverse events (AEs) with efficacy outcomes presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 24 May 2019 According to an Ipsen media release, data will be presented at 2019 ASCO Annual Meeting.
    • 22 May 2019 Results deriving utility values for cost-effectiveness models presented at the 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top